FDA Acting Drug Center Director Tracy Beth Hoeg Removed
Similar Articles
FDA Commissioner Marty Makary Resigns After 13-Month Tenor
FDA Commissioner Marty Makary Removed After Pressure Over Vape Approvals
FDA Commissioner's Status Unclear Amid Reported Push for Removal
HHS Confirms FDA Blocked Publication of Vaccine Studies
Trump Administration Appeals Injunction Against CDC Vaccine Policy Changes
Dr. Tracy Beth Hoeg has been removed from her role as the Food and Drug Administration (FDA) acting drug center director. Dr. Mike Davis, the former deputy director, will replace her. Hoeg stated she was 'fired' and leaves with 'no regrets.'
Facts First
- Dr. Tracy Beth Hoeg removed as FDA acting drug center director.
- Dr. Mike Davis appointed as new acting director.
- Leadership changes follow Commissioner Marty Makary's resignation and Dr. Vinay Prasad's departure.
- Karim Mikhail will take over as acting director of the vaccines center.
- Hoeg led investigations into antidepressants, COVID-19 vaccines, and RSV drugs for children.
What Happened
Dr. Tracy Beth Hoeg has been removed from her position as the acting director of the Food and Drug Administration (FDA) drug center. Dr. Mike Davis will replace her, according to an agency email sent to staff on Friday. Hoeg stated in a social media post that she was 'fired' and added, 'I learn so much and leave with no regrets.' This leadership change follows the resignation of FDA Commissioner Marty Makary earlier in the week and the departure of Dr. Vinay Prasad, the agency's vaccine and biotech chief, last month. Karim Mikhail will take over as acting director of the vaccines center. Hoeg had been leading the FDA's drug program since December, after being promoted from special assistant by Makary. She had no previous government or management experience.
Why this Matters to You
Changes in FDA leadership could affect the pace and direction of drug safety reviews, including investigations into medications you or your family might use. Hoeg led reviews of antidepressants, COVID-19 vaccinations, and injectable RSV drugs for children. The agency's future approach to vaccine recommendations and safety monitoring may evolve under new leadership.
What's Next
Dr. Mike Davis is now the acting director of the FDA drug center. Karim Mikhail will lead the vaccines center. The agency may continue its ongoing reviews and investigations under this new structure. The FDA has not formally announced the findings of a vaccine injury analysis Hoeg led, and its future publication remains uncertain.